Dyax enjoys climbing stock prices

Dyax had a great day Monday. The company released positive late-stage clinical trial findings regarding its drug DX-88 and investors took notice. According to its data, DX-88 reduced the symptoms associated with hereditary angioedema, a genetic blood disorder, and stocks climbed by 15.5 percent, to the company's 2008 peak thus far.  Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.